BAK · Braskem S.A.

Current Thesis

Braskem's restructuring recovery depends on a binding parent plan that preserves listed equity without creditor-driven dilution; the estimated 2026-11-22 creditor-support deadline is the decisive test. Its 2026-08-24 filing covered approximately US$10.9 billion of unsecured obligations and reported support representing 39.6% of affected claims. That filing established a negotiation process, not completed debt relief. Braskem Form 6-K, 2026-08-24.

The material development since the September 6 note is UBS's 2026-09-16 reduction of its American depositary receipt (ADR) price target to $1.50 from $4.00, reported by MT Newswires. The adjusted market close subsequently stood at $1.70 on 2026-09-18, below the September 4 close of $1.89. The narrative is maturing — an inference from the August restructuring announcement, September analyst reassessment and weaker subsequent close; these observations do not establish expanding participation. MT Newswires, 2026-09-16.

Bullish and bearish views on Braskem S.A.

The model's bull view on Braskem S.A. (BAK), in brief: Subsidiary terms preserve residual equity. The bear view: Creditor agreement remains incomplete. The 39.6% support disclosed on 2026-08-24 was sufficient to file, while the company still needed the required approval percentage within 90 days. No subsequent support percentage is established by the evidence available for this refresh.… Both cases follow in full.

Bull Case

• Subsidiary terms preserve residual equity. Stretto's 2026-08-24 review of Braskem Idesa's proposed plan describes one-third of reorganized equity for existing shareholders and elimination of more than US$920 million of funded debt. This supports the possibility of residual equity value, but does not establish the parent's eventual treatment. Stretto case review.
• Operating obligations remain outside negotiations. Braskem's 2026-08-24 filing excludes supplier and customer obligations from the extrajudicial reorganization and says those contracts continue to be fulfilled. This limits the disclosed restructuring perimeter; it does not demonstrate sufficient liquidity through completion. Braskem Form 6-K.

Bear Case

• Creditor agreement remains incomplete. The 39.6% support disclosed on 2026-08-24 was sufficient to file, while the company still needed the required approval percentage within 90 days. No subsequent support percentage is established by the evidence available for this refresh. Braskem Form 6-K.
• Credit impairment is already documented. Braskem disclosed on 2026-08-17 that Fitch had revised its corporate rating to restricted default following nonpayment after contractual cure periods expired. Continued operations therefore cannot be treated as evidence that financial obligations have been resolved. Braskem rating notice.
• Analyst reassessment accompanied market weakness. MT Newswires reported that BAK fell more than 15% during the 2026-09-16 session following UBS's downgrade. UBS's $1.50 ADR target is an attributed valuation opinion, not an established recovery value. MT Newswires.

Setup & Price Structure

The split- and dividend-adjusted daily-bar series records a $1.70 close on 2026-09-18, a three-month decline of 42.0%, and a price 66.1% below its $5.02 trailing-year high. Its 14-period relative strength index was 50.8. These measurements establish a depressed longer-term price structure; the momentum reading alone does not establish a reversal.

The September 16 downgrade coverage is observable attention around a negative event. It does not identify investor positioning or demonstrate crowded ownership. No verified moving-average distance, current short-interest measurement or retail-participation series is available here, so no squeeze or crowding conclusion follows.

The $1.45 level remains the published research invalidation threshold. It is not presented as independently verified, repeatedly tested market support.

Catalyst Calendar (next 30 days)

• 2026-09-24 — Idesa confirmation hearing. Stretto's 2026-08-24 report records a combined disclosure-statement and plan-confirmation hearing under the August 18 scheduling order. Confirmation, rejection or adjournment tests the subsidiary agreement; a subsequent docket update confirming the schedule is not established here. Stretto case review.
• ~2026-11-22, estimated — Parent support deadline. This later event remains decisive because Braskem's 2026-08-24 filing specifies 90 days to obtain the required approval percentage. The calendar date remains an estimate; the filing establishes the duration. Braskem Form 6-K.

What Would Change Our Mind

Failure of the post-filing recovery would be recorded by a weekly close below $1.45. Independently, a filed parent plan issuing equity to financial creditors would invalidate the undiluted-equity case, as would expiration of the creditor-support window without the required approvals.

The successful case requires Idesa confirmation and a binding parent agreement that leaves listed equity outstanding without creditor-driven dilution before the price condition fires. A subsidiary hearing alone cannot establish that outcome: the August 17 subsidiary petition and August 24 parent filing concern separate proceedings.

Correlation Notes

The thesis is a single-company restructuring case. Operating exposure to petrochemical spreads remains relevant: Braskem's Q2 2026 release attributed stronger United States and European results partly to higher international polypropylene spreads. That is an operating relationship, not a measured correlation between BAK and crude oil or a chemical-equity index. Braskem Q2 2026 results.

No synchronized peer-return or currency series accompanies the 2026-09-18 price observations. The available evidence cannot establish that a sector move would offset parent dilution or a failed creditor agreement.